Drug intelligence / Profile preview

IMX-111

Development stage: Discontinued
Lead developer: Immix Biopharma
Modality: Small Molecules

Overview

IMX-111 is a targeted form of IMX-110, being developed by Immix Biopharma for the treatment of cancer. It is described as a first cancer therapeutic utilizing GLUT1 (glucose transporter 1) antibody biomarker targeting coupled with DNA and topoisomerase II inhibition mechanisms. IMX-111 is designed as a tissue-specific biologic built on Immix's TME Normalization Technology platform with proprietary GLUT1 antibody biomarker targeting. The drug is an apoptosis inducer specifically developed for colorectal cancer treatment. As a small molecule drug, it functions through multiple inhibitory mechanisms including DNA inhibition, GLUT1 inhibition, and topoisomerase II inhibition.

Targets

TOP2A (DNA topoisomerase II)DNAGLUT1 (Glucose transporter 1)

Beyond the preview

Go deeper on IMX-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMX-111.

Explore the full profile